


CORPORATE PRESENTATION

February 4th, 2026



FORWARD LOOKING STATEMENTS



Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the control of BioHarvest Sciences, Inc. (the "Company") and could cause the Company's results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy. Although the company believes it has identified a path to profitability there is no assurance that profitability will be achieved as many factors beyond the control of the company could impact its potential for profitability such as changes in consumer preferences, increases in costs and changes in government regulation. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.

Non-GAAP or non IFRS Financial Measures

This presentation includes certain financial measures not prepared in accordance with generally accepted accounting principles ("GAAP") and international financial reporting standards ("IFRS"), including Adjusted EBITDA. These non-GAAP and non-IFRS financial measures are not measures of financial performance in accordance with GAAP and IFRS and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative to measures prepared in accordance with GAAP or IFRS. In addition, our presentation of these measures may not be comparable to similarly-titled financial measures used by other companies. We believe that these non-GAAP and non-IFRS measures, when viewed with our results under GAAP and IFRS and the accompanying reconciliations, provides useful information about our period-over-period results. These non-GAAP and non-IFRS measures are presented because we believe they provide additional information with respect to the performance of our fundamental business activities and are also frequently used by securities analysts, investors and other interested parties in the evaluation of comparable companies. These non-GAAP and non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management in determining these non-GAAP and non-IFRS financial measures.

Market & Industry Data

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For more information, please refer to risk factors discussed in Company's periodic filings with the SEC.

We have filed a registration statement on Form S-3 (No. 333-[289908](#)) with the SEC for the offering to which this presentation relates. Before you invest, you should read the prospectus in that registration statement and other documents we have filed with the SEC for more complete information about BioHarvest and this offering. You may get these documents for free by visiting the SEC website at <http://www.sec.gov>.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

BIOHARVEST INTRODUCTION



BIOHARVEST IS THE INVENTOR OF **BOTANICAL SYNTHESIS** – THE PROCESS OF **ISOLATING** AND **MAXIMIZING THE POTENCY OF PHYTO-NUTRIENTS/MEDICINAL COMPOUNDS** FROM PLANTS FOR COMMERCIAL APPLICATIONS BY GROWING ONLY PLANT CELLS WITHOUT GROWING THE PLANT

COMPANY HIGHLIGHTS



- ✓ Patented Platform with > \$100M USD invested over 17 yrs
- ✓ 20-25 tons Capacity with expected 75 tons available by Q2-27
- ✓ D2C products division with over **\$33M** of TTM Revenue
- ✓ Scalable CDMO platform with numerous signed customers progressing through development
- ✓ Company successfully raised 19.9M USD gross proceeds in November 2025 at public offering @\$7 per share



Q3 RESULTS



(USD \$ in Millions)	Q3 2025	Q3 2024
Revenue	\$9.1	\$6.5
Adjusted EBITDA	(\$0.4)	(\$1.7)

CONSUMER PRODUCTS DIVISION

5 product lines commercialized into 3 Multi-Billion \$ Addressable Categories

>85,000 Active Customers and #1 Resveratrol only Product on Amazon

CDMO DIVISION

4 current customers, robust pipeline



EXECUTIVE LEADERSHIP TEAM



Ilan Sobel
Chief Executive Officer
25+ years developing & executing strategic growth strategies



Dr. Zaki Rakib
Chairman of the Board
30+ years experience developing disruptive technologies



Dr. Yochi Hagay
Chief Technology Officer
20+ years experience in the pharmaceutical & biotech space



Bar Dichter
Chief Financial Officer



Dr. Malkit Azachi
Vice President R&D
20+ years experience developing biotechnologies




Dr. Ilana Belzer
Chief Operating Officer
Extensive experience overseeing biotech companies



VISION


BHST is Addressing Unmet Health & Wellness Needs With Patentable Plant Compounds Produced Consistently & Economically With the Highest Levels of Sustainability



**NORTH STAR OF BHST
IS TO DISCOVER, DEVELOP, MANUFACTURE &
DEMOCRATIZE
LIFE-CHANGING COMPOUNDS FROM PLANTS THAT
CHANGE THE WORLD OF HEALTH & WELLNESS FOR
HUNDREDS OF MILLIONS OF PEOPLE WHILE PRESERVING
THE PLANET FOR GENERATIONS TO COME**

PROPRIETARY TECHNOLOGY PROCESS WHICH ENABLES DEVELOPMENT OF COMPOUNDS FOR NEXT-GEN THERAPEUTIC SOLUTIONS WITH LOW CAPEX REQUIREMENTS ENABLING HIGH ROC

WE ONLY REQUIRE THE PLANT ONCE TO **MIRROR**, **MAGNIFY** AND **MULTIPLY** PLANT CELLS WITH UNIQUE PHYTOMEDICINAL COMPOUNDS.



- ▶ A Global Leader in Plant Cell Biology with 15+ Years of Development and ~\$100M Invested in the Platform
- ▶ 14 Granted Patents – Multiple Pending
- ▶ Current Facility Cost of Capital of \$5M USD can generate \$60M USD in Revenue Per Year at full capacity



THE BOTANICAL
SYNTHESIS
COMPANY

NASDAQ: BHST




THE BOTANICAL
SYNTHESIS
COMPANY

QUERCETIN

CATECHIN

PICEID
RESVERATROL
x100



ANTHOCYANINS

TANNINS



TURNING PLANTS INTO A SCIENTIFICALLY RELIABLE SOURCE OF PATENTABLE BIOLOGICAL COMPOUNDS

Botanical Synthesis Offers Significant Advantages in Production of Simple and Complex Compounds




Consistency

Production inherently has a degree of control not possible in nature.



Patentability

Botanical compositions patentable given concentrations not possible in nature.



Optimal Bioavailability

Maintaining the metabolites original molecular conformation while enabling the elicitation of certain important compounds.



Cleanliness / Purity

Inherently clean process due to aseptic growth conditions.



Environmental Sustainability

Botanical synthesis uses much less resources, including land, water and electricity. In addition, growing a plant cell only requires a 'real' plant one time for future replication.



Economic Viability

Cells are grown directly in bioreactors and harvested every 3 weeks which creates up to 17 harvest cycles per year. The result is an order of magnitude lower cost of production.



Non-GMO

Molecular structure of the plant compounds are not changed in any way.

TWO GROWTH ENGINES TO DRIVE GROWTH

Providing Validation For Botanical Synthesis And Strategic Optionality



DIRECT TO CONSUMER – PACKAGED PRODUCTS

Commercial

Expected 2026 Launch

TBD



Vinia
Grapes



Olivia
Olives



Pomia
Pomegranates



Capsules



Daily Chews



Hydration



Coffee



Espresso



Tea

CDMO Services

APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR:

- MULTIPLE VERTICALS
- 4 DEALS SIGNED + ROBUST PIPELINE
- EACH MULTI-BILLION MARKET OPPORTUNITIES



DISCOVERY



DEVELOPMENT



ROYALTY BASED
MANUFACTURING
PARTNERSHIP

INTRODUCING VINIA®: OUR FLAGSHIP RED GRAPE CELL-DERIVED DIRECT-TO-CONSUMER NUTRACEUTICAL PRODUCT

- VINIA® is BioHarvest's first commercial product. Proof of concept and market acceptance with over **\$75M in lifetime sales** since May 2021 USA launch.
- Breakthrough Red Grape Cell Powder that is **Clinically shown to Significantly Increase Arterial Dilation, increasing blood flow and delivery of oxygen and nutrients to body's organs., tissues and cells**
- **Key Benefits: Increased Physical Energy & Mental Alertness, Healthy Blood Pressure Support, Reduces Oxidation of LDL Cholesterol, Reduces Oxidative Damage to Cells**
- Have over **85,000 active customers** with **~90% of online Vinia.com revenue is subscription**, validating the demand for products created using inherent advantages of Botanical Synthesis
- **Growing customer satisfaction (4.7/5 average rating from 10,300+ verified online reviews).** Significant base of healthcare professionals using VINIA via D2D channel
- Available in the U.S., have regulatory approval in Canada , with additional regulatory efforts underway other proprietary markets




on AMAZON FOR RESVERATROL ONLY PRODUCTS

PRODUCTS ANCHORED IN SCIENCE & BACKED BY CLINICAL TRIALS

VINIA® is patent-protected with **3 peer-reviewed studies** and **8 scientific studies**

70% INCREASE IN ARTERY DILATION

Our clinical trial showed that VINIA increased the dilation of arteries by at least 70% for **each person who took VINIA daily for 90 days.***



120% Increase in Nitric Oxide



Our in vitro studies show that VINIA boosts nitric oxide production by 120%, this helps blood vessels dilate to promote proper blood flow.

50% Decrease in ET-1

Our in vitro study shows that VINIA decreases Endothelin-1 by 50%, a peptide that increases as you age, constricts blood vessels and slows down blood.

Clinical trial published in peer reviewed scientific journals

bioharvest.com/clinical-studies



OUR DISRUPTIVE CATEGORY PLAYBOOK ACCESSES MAJOR BILLION \$ CATEGORIES



USA HEART HEALTH, ENERGY HEALTH & MENTAL ALERTNESS MARKET – \$13 BN



MAY- 2021



JUNE - 2025



Coming Soon

USA HYDRATION MARKET – \$13 BN



December Launch

USA FUNCTIONAL COFFEE AND TEA MARKET – \$5 BN



DEC- 2023



Coming Soon



DEC- 2024



JUNE- 2025

OUR BREAKTHROUGH POSITIONING



>\$1 BILLION p.a

45 CAL PER
STICK




BETTER BLOOD FLOW.
BETTER HYDRATION.

25 CAL




>\$200 MILLION p.a

10 CAL



REPEATING THE VINIA PLAYBOOK: PIPELINE OF OLIVE & POMEGRANATE CELLS



Business Model Can be Easily Replicated Across New Plant Compounds
Expectation to Begin Selling Olive Compound to Consumers in 2026



Increase **Verbascoside**
concentration

At least **15x**
Versus in a regular Olive



Increase **PGG Polyphenol**
(1,2,3,4,6-pentagalloyl glucose)

At least **10x**
Versus in a regular pomegranate

ADDRESSING CONSUMER NEEDS THROUGH NEW COMPOUNDS

- **Olives:** Providing at least **15X** concentrated amounts of Verbascoside concentration vs. a regular olive: a compound with antioxidant, anti-inflammatory and antineoplastic properties ¹
- **Focus on Liver Health or Cognitive Age Decline – 2026 Launch**
- **In-vitro trials complete**, which indicate that BHST olive cells could protect against a cause of non-alcoholic fatty liver disease
- **Pomegranates:** Providing at least **10X** concentrated amounts of PGG Polyphenol: a compound with anti-microbial, anti-diabetic, anti-inflammatory and anti-tumor properties ²
- **Focus on Brain Health**

MIRRORING THE VINIA PLAYBOOK

- Olives and Pomegranate Cell powders can be expanded across Hot Beverages, Chews, Hydration Powders, Skincare and more

SELL THROUGH OPPORTUNITIES

- Further integrate consumers into the BioHarvest ecosystem, cross-selling incremental products to a loyal, captive audience

1) <https://www.sciencedirect.com/science/article/abs/pii/S0944711323003884>
2) <https://www.sciencedirect.com/science/article/abs/pii/S1756464617304334>

BIOHARVEST DISTRIBUTION STRATEGY FOR D2C BUSINESS:

Significant untapped potential in new major channels and geographies





Backed by 17 Years Innovat



~95% of Business

~80% of Revenue Today via VINIA.COM

\$33M
Revenue
Trailing 12 Months

CURRENT SCALE HAS CREATED LEVERAGE WITH MAJOR UNTAPPED DISTRIBUTION EXPANSION OPPORTUNITIES

1. Proprietary BioHarvest Built Channel – VINIA Health Pro’s



300 Health Practitioners, Trainers, Coaches by end 2025

2. Other Major E-Commerce Platforms



90% International/10% USA



3. Selective Strategic Retailers



4. Geographic Expansion



amazon

~20% of Revenue Today

TWO GROWTH ENGINES TO DRIVE GROWTH

Providing Validation For Botanical Synthesis And Strategic Optionality



DIRECT TO CONSUMER – PACKAGED PRODUCTS

Commercial

Expected 2026 Launch

TBD



Vinia
Grapes



Olivia
Olives



Pomia
Pomegranates



Capsules



Daily Chews



Hydration



Coffee



Espresso



Tea

CDMO Services

APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR:

- MULTIPLE VERTICALS
- 4 DEALS SIGNED + ROBUST PIPELINE
- EACH MULTI-BILLION MARKET OPPORTUNITIES



DISCOVERY



DEVELOPMENT



ROYALTY BASED
MANUFACTURING
PARTNERSHIP

CDMO ENGINES FOR GROWTH



PHARMA & BIOTECH

SUPER HIGH MARGIN COMPOUND
REPLACEMENT & NEW COMPOUND
DEVELOPMENT

65% OF FOCUS
>\$5,000 KG

DEAL #1
 Nasdaq -Listed
Pharma Company



NUTRACEUTICALS

DEVELOPMENT OF COMPOUNDS TO DRIVE
DIFFERENTIATION IN MAJOR COMPETITIVE
PROFIT POOLS (BEETS, ASHWAGANDA)

10% OF FOCUS
> \$700 KG

DEAL #4

Saffron Tech




COSMETICS

DEVELOPMENT OF NEW HIGH MARGIN
COMPOUNDS THAT WILL DRIVE INDUSTRY
DIFFERENTIATION FOR 2-3 GLOBAL PLAYERS

15% OF FOCUS
>\$1,500 PER KG

DEAL #4
MULTI-BILLION \$
CONSUMER FUND



NUTRITION & SWEETENERS

Anchored by Dec. 2024 Deal with Tate & Lyle

DEVELOPMENT OF SUPER HIGH VOLUME / LOWER MARGIN
COMPOUNDS THAT WILL CHANGE THE FOOD CHAIN &
FORCE BHST TO BECOME THE LOWEST COST PRODUCER OF
COMPOUNDS

10% OF FOCUS
>\$300 KG

DEAL #2


← Higher Margin | Lower Volume

Lower Margin | Higher Volume →

STAGED GATE DEVELOPMENT APPROACH TO ENSURE SUCCESS WHILST GENERATING REVENUE

NEW DISCOVERY Stage



**SHORT LIST OF PLANT
COMPOUNDS FOR
CUSTOMER**

1 MONTH

Stage 1



PREDICTOR & SELECTOR

6 -9 MONTHS

Stage 2



**CORRECTOR &
SAMPLER**

6 – 9 MONTHS

Stage 3



**LARGE SCALE &
PRODUCER**

6 – 9 MONTHS

MANUFACTURING



**INDUSTRIAL &
COMMERCIAL**

CONTINUOUS

\$2.5-3M in REVENUE & BETWEEN 18-27 MONTHS

ROYALTY BASED

A PATENTABLE MASS-PRODUCIBLE BOTANICAL COMPOSITION

DISCOVERY PHASE

BIOHARVEST AI WORKFLOW



INDICATION-BASED INITIAL SCREENING

AI identifies plant candidates based on:

- Scientific evidence (MOA, trials, patents)
- Unique value proposition (efficacy, rarity, enhancement potential)
- Prior success in tissue culture



MOA & TISSUE CULTURE FILTERING

- Narrowed to smaller number of plants with activity in ≥ 2 biological pathways
- Compatibility with tissue culture platform confirmed



FEASIBILITY & PRODUCT ANALYSIS

Evaluation of:

- Active ingredients & formulation
- Patentability & regulation
- Sourcing & safety
- AI-driven process optimization (monitoring, CV, algorithms)



FINAL SHORTLIST: 4–5 PLANTS

Multi-pathway efficacy & full scalability within BioHarvest system

CORE STRENGTHS

Proprietary AI trained on rare plant biology & biosynthesis

Expertise in botanical patenting & global regulations


Proven full-scale production from indication to market



THE BOTANICAL
SYNTHESIS
COMPANY

THE CDMO SALES FUNNEL: CURRENT CUSTOMER PROGRESS

BOTANICAL SYNTHESIS LAB-TO-CUSTOMER PROCESS IN FULL EFFECT



VINIA®



Olive Cell Compound



2026 Planned Launch

Nasdaq-listed Pharma



Milestone Advancement of CDMO Client to Stage 2 Achieved in Q1 2025

CDMO Client
(Announced October 2025)



Fragrance CDMO Client
(Announced May 2025)



Nutrition & Sweetener CDMO Client



Pipeline as of May 2025

CURRENT CUSTOMER FUTURE REVENUE POTENTIAL CAN DELIVER ESTIMATED >\$50M IN ANNUAL REVENUE IN COMMERCIAL MANUFACTURING PHASES

	INDICATION/USE	CURRENT MARKET SIZE	BIOHARVEST ADVANTAGE	BHST OWNERSHIP IN COMPOUND	POTENTIAL EST ANNUAL REVENUE BY PROJECT AT MANUFACTURING PHASE 2+YRS OUT
Pharma CDMO Client	Pharmaceutical	Confidential	Product Consistency Supply Chain Availability Pricing Stability Control of Supply Chain	N/A	\$5M-\$10M (EST \$5M/Ton)
Fragrance/Oil CDMO Client (Announced May 2025)	Major Premium Fragrance	*** \$10 Billion 5 YR CAGR of 6.4%	Major Cost Advantage Product Consistency Sustainability Impact	Not Announced Yet	\$20M-\$30M (EST \$1.5M/Ton)
 Saffron Tech Saffron CDMO Client (Announced October 2025)	Medical Nutraceutical Cosmetics	** \$1.4 Billion 5 YR CAGR of 6.4%	Product Consistency Superior Potency/Efficacy Enhanced Bio-Availability & Solubility Major Cost Advantage	25% BHST	\$15M-\$20M (EST \$1M/Ton)
 Nutrition & Sweetener CDMO Client	Natural Zero Calorie Sugar Replacement	* \$27.2 Billion 5 YR CAGR of 6.6%	Consistency Taste Control Sustainability Non-GMO	N/A	\$10M-\$15M (EST \$300k/Ton)

*Fortune Business Insights: Natural Sweeteners Market Size, Share & Industry Analysis, By Type (Honey, Molasses, Date Palm, Sugar Alcohol (Xylitol, Mannitol, Sorbitol, and Maltitol), Stevia, and Others), By Application (Food and Beverage (Bakery, Confectionary, Beverages, and Others), Pharmaceuticals, and Personal care and Cosmetics), and Regional Forecast, 2025-2032 Source: <https://www.fortunebusinessinsights.com/industry-reports/natural-sweeteners-market-100553>

**Mordor Intelligence -Saffron Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)Source: <https://www.mordorintelligence.com/industry-reports/saffron-market>

***Straits Research



IN-HOUSE BIOTECH MANUFACTURING AND R&D FACILITIES



THE BOTANICAL
SYNTHESIS
COMPANY

World Class Biological Production and R&D Team in Israel
Best in Class ROC given low Capex Requirements

- Production and Corporate facility located in Yavneh, Israel
- R&D offices located in Rehovot, Israel

Yavneh Facility #1

25 metric ton per year production capacity

(est. **\$60M of product**/annum from one time Capex investment of **\$5M USD**)

- Optimized for industrial production with a Botanical Synthesis
- Produces unique plant compounds using a fraction of the time, space, electricity, water and manpower required for conventional agriculture

Yavne Facility #2 (in process)

80,000 sq. ft. Property

Includes 12 clean rooms, and space for up to 100 metric ton production facility

- Includes all R&D functions
- Allows CDMO customers to experience complete end-to-end development and manufacturing service

FUTURE TARGET: Future plans to construct a 200 metric ton manufacturing facility in the United States to be completed by end of 2029

FINANCIAL HIGHLIGHTS


Quarterly Revenue*
\$ in Millions



THE BOTANICAL
SYNTHESIS
COMPANY

- Investing for Growth & Profitability:** Investing heavily to scale VINIA[®] sales, incremental new products and defined path to adj. EBITDA breakeven in the near term with growing Gross Profit Margins
- CDMO Optionality:** Long-term royalty potential through CDMO services business unit
- Capital Raising of 19.9M USD gross proceeds in Nov 2025:** Fully funds near term capex needs

	LTM September 2025	Q3 2025	FY2024	FY2023	FY2022
(USD \$ in Millions)					
Revenue	\$32.8	\$9.1	\$25.2	\$12.7	\$5.5
Gross Profit Margin	N/A	61%	55%	45%	22%
Adjusted EBITDA	(\$4.9)	(\$0.4)	(\$5.9)	(8.7)	(8.4)



*As of 9/30/2025

BIOHARVEST INVESTMENT HIGHLIGHTS



1

**Breakthrough Technology
Bring Life-changing
Compounds To Commercial
Markets**

2

**Successful D2C Health &
Wellness Products Division**

Validated Botanical Synthesis Technology

3

**Expansive CDMO
Opportunity**

*4 commercial deals signed + robust
pipeline*

4

**Proprietary New Compound
Discovery Phase to Drive
Future Growth**

5

**Mature Technology with
Significant Manufacturing
Operations Set Up with Low Cost
of Capital. Fully Funded for Near
Term Capital needs**

6

**Attractive Operating Model
for CDMO and Consumer
Divisions with Significant
Optionality**

CONTACT US

Investor Relations

Justin Meiklem

Direct: 778.686.3855

justin@bioharvest.com

Main: (604) 622.1286

investors@bioharvest.com

BioHarvest Sciences (NASDAQ: BHST)
625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canada
www.bioharvest.com

